Technology · Health & biomedicine / Therapeutics & platforms

Microbiome therapeutics (live biotherapeutic products)

Live biotherapeutic products (LBPs) — standardized, GMP-manufactured microbial consortia approved as drugs for recurrent C. difficile, inflammatory bowel disease and immuno-oncology support.

Maturity 5/9 Risk: medium Pharma & biologics US · CN · EU Science: why it works → verified 2026-07-01 · 6 Sources (0 independent)

1 · What it gives

Live biotherapeutic products (LBPs) are a class of biological drugs containing live microorganisms — primarily bacteria, but also phages or yeasts — engineered to treat disease by modulating the composition and function of the human microbiome. Unlike dietary probiotics, LBPs undergo full clinical development and pharmaceutical licensing by the FDA, EMA and NMPA for specific indications. The sector pivoted from raw faecal microbiota transplantation (FMT) toward defined consortia: rationally assembled mixtures of pure clonal strains grown individually under GMP, eliminating donor variability and pathogen-transfer risk while holding titres of 10^10–10^11 CFU per dose.

The key directions of microbiome therapeutics are:

Recurrent C. difficile infection (CDI): oral spore or consortia drugs that restore gut ecology after antibiotic failure — the first two FDA-approved LBPs (Vowst, Rebyota) target this indication.
Inflammatory & immune disorders: defined consortia for ulcerative colitis, Crohn’s disease, irritable bowel syndrome and acute graft-versus-host disease (aGVHD).
Immuno-oncology modulation: live consortia that reprogram the gut to raise response rates to immune-checkpoint inhibitors in melanoma and solid tumours.
Gut–brain & metabolic axis: candidates addressing neurodegeneration (Alzheimer’s, ALS) and metabolic disease through the microbiome–brain signalling axis.

Sectoral value chain#

[Microbiome screening & AI design] ──> [Clonal cell banking] ──> [Anaerobic fermentation]
                  │                                │                          │
        (Metagenomics, strains)        (Master cell banks)        (Bacterial biomass)
                                                                          │
[Acid-resistant encapsulation] <── [Lyophilization & stabilization] <────┘

Value chain levels#

Level	Description	Key inputs/outputs
Upstream (design & strains)	Screening healthy donors, AI metagenome mapping of the gut, isolating pure target strains and building Master Cell Banks (MCB).	In: Donor biosamples, metagenome databases. Out: Characterized pure clonal strains in a cell bank.
Formulation (consortia design)	Computing strain synergy (e.g. butyrate producers) and combining several strains in fixed stoichiometric ratios.	In: Individual clonal cultures. Out: Multi-strain consortium specification.
Bioreaction (fermentation)	Cultivating strict anaerobes in sealed bioreactors with oxygen-free gas mixtures at redox potential below -300 mV.	In: Pure inoculum, anoxic growth medium. Out: High-viability anaerobic biomass.
Downstream (concentration)	Separating biomass by tangential-flow filtration (TFF) under a nitrogen blanket, 10–20x concentration.	In: Culture broth. Out: Dense wet cell concentrate.
Stabilization (lyophilization)	Freezing with cryoprotectants and vacuum-drying to a dormant state with viability loss under 0.5 log10.	In: Wet concentrate, protectant matrix. Out: Dry viable lyophilisate powder.
Delivery (encapsulation)	Filling enteric HPMC capsules and blister-packing with oxygen absorbers for ambient-chain stability.	In: Lyophilized powder, HPMC capsules. Out: Finished drug product.

Cross-cutting technologies of the sector:

Anoxic bioprocessing: Nitrogen/CO2/H2 gas blankets keep reactor redox below -300 mV to culture obligate anaerobes such as Faecalibacterium prausnitzii and Akkermansia muciniphila.
AI-driven consortia design: Machine-learning models predict metabolic cross-feeding between dozens of strains to restore stable gut homeostasis.
Colon-specific delayed release: HPMC capsules with a pH-responsive polymer coat dissolve only above pH 6.8 in the terminal ileum, shielding bacteria from gastric acid and bile.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

1
MCB vial thaw
A working cell-bank vial of a single strain (e.g. Bacteroides thetaiotaomicron) is retrieved from liquid-nitrogen storage at -196°C; thaw and pre-culture happen inside an anaerobic laminar hood under an N2/H2 atmosphere, with purity checked by PCR and selective plating.
2
Anaerobic fermentationFermentation & cultivationBiogas, compost & waste valorisation
The seed is transferred to a 1000–5000 L bioreactor charged with a vegan yeast-hydrolysate medium free of animal proteins; temperature holds at 37°C, pH is auto-controlled with sterile base, and the headspace is continuously sparged with a 90% N2 / 10% CO2 mix. Harvest occurs at late-exponential phase for maximum drying-stress resilience.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ GMP 500 m3
“Technology: microbial fermentation with ~500 m3 fermentation capacity; 15+ patents; developed/upscaled probiotic production technologies.”
Fermelanta Japan
3,000 L pilot scale
“We transform the traditional supply chain depending on agricultural cultivation and extraction into a next-gen microbial fermentation process that can offer low-cost and …”
Ajinomoto Japan
✓ GMP industrial scale
“It specializes in amino acid fermentation technology, applying it to seasonings, processed foods, frozen foods, and healthcare solutions.”
Taiwan Sugar Corporation (TSC) Taiwan
500,000 tons pilot scale
“It refines sugar (including refined white sugar, golden brown sugar, fine granulated sugar and invert sugar syrup), produces bio-based chemicals/biotech outputs (alcohol, …”
3
TFF concentration
The broth is cooled to 8°C to slow metabolism and fed to a tangential-flow filtration skid (0.22 µm cutoff) pre-purged with nitrogen; the slurry is concentrated 10–20x and washed with sterile saline to a titre around 10^10–10^11 CFU/ml.
4
Strain blending & cryoprotectant dosingStrains & cell linesFormulation & blending
The wet concentrate moves to a jacketed mixer under inert gas; a sterile cryoprotectant matrix (trehalose, maltodextrin, sodium glutamate, ascorbic acid antioxidant) is dosed in, and for a multi-strain consortium the individual strain concentrates are combined in strictly controlled stoichiometric ratios per the therapeutic formulation.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ GMP 500 m3
“This is a satellite blending, mixing and formulation facility, located at Vashind near Shahapur and dedicated to the company’s Animal Nutrition business.”
Fermelanta Japan
3,000 L pilot scale
“is a Japan-based biomanufacturing/synthetic biology startup engineering fast-growing E.”
Tsingke Biotechnology China
“Tsingke Biotech is a leader in synthetic biology, committed to building a world-class gene factory.”
CHITOSE Japan
industrial scale
“STABLE CELL LINE DEVELOPMENT SERVICE”
5
LyophilizationPurification & downstream
The biomass–protectant mix is spread on stainless trays under a nitrogen curtain; product is frozen to -45°C at 1°C/min, then primary drying raises temperature to -10°C to sublimate free water and secondary drying at +20°C removes bound moisture. The dry cake is milled in a sealed mill under dry nitrogen (humidity below 3%), keeping viability loss under 0.5 log10.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ GMP 500 m3
“Development of robust, scalable fermentation and downstream processing (production and recovery/yield optimization).”
HLB Genex (ex-GenoFocus) South Korea
industrial scale
“With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
Esco Aster Singapore
5,000 L industrial scale
“Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”
6
Encapsulation & nitrogen blister fillFormulation & blending
The lyophilized powder is blended with magnesium stearate and silicon dioxide excipients and dosed into enteric HPMC capsules on an automatic filler under inert gas; capsules are blister-packed in barrier Alu-Alu foil with each cell nitrogen-flushed. Each batch is released only after anaerobic-plate viable counts (CFU/capsule), 16S rRNA strain-ratio confirmation, LAL endotoxin testing and acid-disintegration checks.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ GMP 500 m3
“This is a satellite blending, mixing and formulation facility, located at Vashind near Shahapur and dedicated to the company’s Animal Nutrition business.”
Taiwan Sugar Corporation (TSC) Taiwan
500,000 tons pilot scale
“It refines sugar (including refined white sugar, golden brown sugar, fine granulated sugar and invert sugar syrup), produces bio-based chemicals/biotech outputs (alcohol, …”
SyAqua Group Thailand
“vannamei genetics (broodstock, nauplii, and post-larvae) built on genomic selection/marker-assisted selection plus quantitative genetics (BLUP), with disease resistance screening …”

4 · Who delivers

Matched suppliers (matched automatically)

HLB Genex (ex-GenoFocus)	South Korea	Producer	active
ImpacFat	Singapore	Producer	active
Codexis	United States	Producer	active
ToolGen (KOSDAQ)	South Korea	Not classified	active
ILRI	Kenya	Research / RTO	active
Ninjacart	India	Producer	active

Leading companies and institutes (from the brief)

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Seres Therapeutics	🇺🇸 USA	Vowst (SER-109)	Ethanol-fractionated Firmicutes spores from donor material	commercial
Vedanta Biosciences	🇺🇸 USA	VE303, VE202	Pure clonal consortia from Master Cell Banks, dedicated GMP plant	operating
MaaT Pharma	🇫🇷 France	MaaT013, MaaT033	High-diversity donor-ecosystem conservation, Lyon automated GMP	operating
Ferring Pharmaceuticals	🇨🇭 Switzerland	Rebyota (RBX2660)	First-in-world approved microbiota liquid enema	commercial
Microbiotica	🇬🇧 United Kingdom	MBT093	Reference Genome Database for precise strain mapping	operating
Xbiome	🇨🇳 China	XBI-302, XBI-101	Machine-learning strain/donor-matching platform	operating

5 · Rules & route to market

United States

The United States leads LBP commercialization, having granted the first oral live-microbiome drug approval and hosting the deepest venture-funded pipeline.

Vowst approval, Vedanta GMP platform, donor-FMT retreat#

FDA approval of Vowst (SER-109): Seres Therapeutics’ oral Firmicutes spore fraction, co-marketed with Nestle Health Science, was FDA-approved in April 2023 for recurrent CDI prevention — the first oral LBP, opening large-scale investment into the sector.
Vedanta Biosciences clonal platform: Vedanta shifted from donor material to fully synthetic clonal consortia, commissioning a dedicated US GMP plant that produces defined-consortium drug VE303 directly from its own Master Cell Banks.
Regulatory retreat from donor FMT: The FDA progressively tightened oversight of stool-based FMT over standardization and pathogen-transmission risk, prioritizing molecularly characterized LBP drug forms.

European Union

The European Union is setting the global regulatory template for live biotherapeutics through European Pharmacopoeia standards and hosts a clinical leader in oncology microbiome therapy.

Ph. Eur. standards, MaaT Pharma clinical lead, PRI alignment#

European Pharmacopoeia (Ph. Eur.): EDQM issued a dedicated general chapter on live biotherapeutic products for human use, fixing common standards for purity, viability, stability and absence of antimicrobial-resistance genes across EU states.
MaaT Pharma (France): A Lyon-based pioneer in high-diversity microbial ecosystems for oncology; lead drug MaaT013 reached pivotal phase 3 in Europe for acute graft-versus-host disease with an automated GMP plant.
Pharmabiotic Research Institute (PRI): An EU consortium aligning academia, biotech and the EMA through scientific-advice procedures to lower regulatory barriers for microbiome drugs.

China

China is building an integrated microbiome-therapeutics industry that couples large-scale gut-metagenome science with AI strain design and traditional-medicine co-formulation.

Gut-microbiome mapping, AI platforms, TCM integration#

Chinese Gut Microbiome Project: A CAS-led national programme has built metagenome profiles across hundreds of thousands of regional subjects, surfacing endemic protective strains as feedstock for new therapeutic lines.
Xbiome AI platform: Shenzhen-based Xbiome uses deep learning for FMT donor matching and AI design of personalized multi-strain drugs for oncology patients (candidate XBI-302), running clinical trials in China and the US.
TCM co-formulation: A distinctive R&D strand pairs LBPs with plant polysaccharides from traditional medicine that act as selective prebiotics to boost engraftment and activity of therapeutic strains.

6 · Money: tenders & grants

Grant	Enhancing ecodesign and circularity of construction products European Commission · EU	Sep 22, 2027 341 days
Grant	Replacing hazardous substances in biocidal products European Commission · EU	Sep 22, 2027 341 days
Grant	First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States	Oct 15, 2027 364 days
Grant	Microbiome for terrestrial livestock sustainability and health within a One Health approach European Commission · EU	Sep 23, 2027 342 days
Grant	Open topic: Using the Circular Cities and Regions Initiative to strengthen urban manufacturing in support of … European Commission · EU	Apr 8, 2027 174 days

7 · Tech stack & innovations

The LBP manufacturing stack is built around keeping oxygen-sensitive organisms alive from cell bank to capsule.

Strict anaerobic cultivation (Anoxic Bioprocessing):
- Sealed stainless bioreactors continuously sparged with high-purity N2/CO2 hold redox potential below -300 mV, keeping obligate anaerobes (Bacteroidetes, Clostridiales) viable through harvest.
Anaerobic lyophilization (Anaerobic Lyophilization):
- Biomass mixed with trehalose/sucrose/antioxidant/peptide cryoprotectants is frozen to -45°C at 1°C/min and vacuum-dried, holding viability loss under 0.5 log10.
Colon-specific encapsulation (Delayed Release Encapsulation):
- HPMC capsules coated with a methacrylic-acid polymer stay intact below pH 5.5 and dissolve above pH 6.8, releasing live bacteria directly in the terminal ileum.

Sources 6 · 0 independent · 6 producer sites

Producers' own sites 6

Seres therapeutics producer checked 2026-04-23 · link not kept
Vedanta biosciences producer checked 2026-04-03 · link not kept
Maat pharma producer checked 2026-03-23 · link not kept
Ferring pharmaceuticals producer checked 2026-06-06 · link not kept
Microbiotica producer checked 2026-05-27 · link not kept
Xbiome producer checked 2026-07-01 · link not kept